drugset / Trial / NCT07108868
A Phase I Dose Finding Study of MB-CART2219.1
NaSingle-groupOpen-labelTreatment
Summary
A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignancies
Timeline
- Start
- 2025-06-23
- Primary completion
- 2027-03
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MB-CART2219.1 | Unknown | 250000 cells/kg | — |
| Subject | MB-CART2219.1 | Unknown | 500000 cells/kg | — |
| Subject | MB-CART2219.1 | Unknown | 1e+06 cells/kg | — |
| Subject | MB-CART2219.1 | Unknown | 2e+06 cells/kg | — |